Gelion plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GELNF research report →
Price Chart
About the company
Gelion plc specializes in the global development, manufacturing, and commercialization of innovative battery systems. A key offering in their portfolio is the Endure range of zinc-bromide batteries. These advanced energy storage solutions are deployed across a diverse array of applications, including remote off-grid power, industrial and commercial facilities, specialized industrial light towers, critical grid support services, and the integration of solar and wind renewable energy.
- CEO
- Matthew Wood
- IPO
- 2021
- Employees
- 50
- HQ
- Norwich, NSW, GB
Get TickerSpark's AI analysis on GELNF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $65.16M
- P/E
- -6.80
- Fwd P/E
- 7.02
- PEG
- -0.27
- P/S
- 983.23
- P/B
- 3.29
- EV/EBITDA
- -5.52
- Div Yield
- 0.00%
- Gross Margin
- -1093.88%
- Op Margin
- -16224.49%
- Net Margin
- -13169.39%
- ROE
- -40.88%
- ROIC
- -42.02%
Latest fiscal year · YoY change
- Revenue
- $48.21K-94.7%
- Gross Profit
- $-527,360-49.7%
- Op Income
- $-7,821,858
- Net Income
- $-6,348,987-6.0%
- EPS
- $-0.03+26.2%
- OCF Growth
- -6.5%
- FCF Growth
- -13.2%
- 52W High
- $0.30
- 52W Low
- $0.17
- 50D MA
- $0.19
- 200D MA
- $0.23
- Beta
- 0.46
- RSI (14)
- 97
- Avg Volume
- 2.10K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Gelion said it delivered better-than-expected FY2026 results while sharpening its focus on NES sulfur cathodes and winding down lower-priority activities to push toward commercialization.· October 22, 2026
- Adjusted EBITDA loss was GBP 4.1 million, better than market expectations of GBP 4.4 million.
- Pro forma cash and cash equivalents were GBP 9.6 million at 30 June, and management said this was circa 20% above market expectations.
- Grant-funded R&D rose to 63.2% of the development program, up from 49.8%, helping offset lower integration services revenue.
- Management is winding down the integration solutions business, expecting around GBP 800,000 of annual savings to redeploy into the core NES program.
- The company said it expects modest commercial revenue in FY2027, with the Mitsui Kinzoku funded JDA already starting to contribute cash.
Gelion reported an adjusted EBITDA loss of GBP 4.1 million versus market expectations of GBP 4.4 million. Pro forma cash and cash equivalents were GBP 9.6 million at 30 June, which management said was circa 20% above market expectations. Revenue was pressured by the collapse in integration services revenue, which was approximately GBP 900,000 in FY2025 and almost nil in FY2026. Grant-funded R&D covered 63.2% of the development program in FY2026 versus 49.8% previously. Forward guidance: management expects modest revenue in FY2027, continued use of roughly GBP 5 million annual cash spend, and further revenue contribution from funded partnerships including Mitsui Kinzoku; they also said integration solutions wind-down should save around GBP 800,000 per year.
Matt Wood framed the year as one of “momentum” in technology validation, market traction and preparation for scale, saying Gelion’s NES sulfur cathode is now being validated across defense, drones and EV-related programs. He emphasized that the company is simplifying its portfolio: exiting integration solutions, reviewing recycling, and prioritizing commercialization of NES over broader discovery efforts. His tone was confident and focused, with repeated emphasis on clear strategy, partnership-driven execution and a licensing model rather than building a full manufacturing footprint.
Amit Gupta said Gelion exceeded market expectations across key financial metrics and stressed disciplined cost control and non-dilutive funding. He highlighted adjusted EBITDA loss of GBP 4.1 million, pro forma cash of GBP 9.6 million, and that the company stayed within the roughly GBP 5 million annual cash-spend envelope communicated previously. He also said 63.2% of development spend was grant-funded, the business had delivered more than promised within the allocated capital pool, and the integration solutions wind-down should save about GBP 800,000 annually. On revenue, he said FY2027 commercial revenue should be modest at first, with Mitsui Kinzoku’s funded JDA starting to contribute cash and more funded agreements improving revenue recognition.
Investors asked about share-price volatility, sodium-ion competition, commercialization timing, scaling risk, and the path to commercial orders. Management said share price is affected by liquidity and macro factors, not just company progress, and that they are engaging more actively with investors. On sodium-ion, they said it is not a threat for their target markets and could be an opportunity later; on timing, they said battery qualification simply takes time and there is no barrier other than progressing through the usual development path. They also said commercial orders should ultimately flow through partners in a licensing model, while revenue in the near term will come from funded agreements and modest FY2027 commercial income.
The call showed tangible technical progress: TDK pouch-cell durability, QinetiQ drone-relevant power performance, and National Lab of the Rockies results that management said matched or beat standard lithium-ion performance on rate capability. Management also said the product works across Asia, Europe and the U.S. “out of the box,” which supports the licensing narrative. Financially, the company beat expectations, maintained cash discipline, and increased the share of development funded by grants.
Commercialization is still early, and management repeatedly said battery qualification takes time; they do not expect meaningful commercial revenue until FY2027 and even then it will be modest. The integration solutions business is being wound down because it lacks a sustainable competitive advantage and the market has become commoditized and oversupplied. Revenue also fell sharply as integration services disappeared, and the company still needs to prove scaling, pilot production and eventual order conversion across multiple partner programs.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 67.6%
- Shares Outstanding
- 229.42M
- Float Shares
- 155.11M
Our GELNF coverage
Recent articles, reports, and earnings notes.
No research on GELNF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GELNF report →Gelion plc (GELNF) Q4 2026 Earnings Call Transcript
seekingalpha.com · Oct 22
Nasdaq holds steady in countdown to Nvidia earnings
proactiveinvestors.com · Aug 26
Intuit's earnings miss is largely an accounting illusion, but the revenue slowdown is real
proactiveinvestors.com · Aug 26
Wall Street futures tick higher as inflation meets expectations
proactiveinvestors.com · Aug 12
Gelion plc (GELNF) Shareholder/Analyst Call Transcript
seekingalpha.com · Jul 2
Merck, AbbVie probed by US lawmakers over China clinical trials: report
proactiveinvestors.com · Jun 30
Gelion appoints Matthew Wood as chief executive
proactiveinvestors.com · Jun 30
e.l.f. Beauty bets on hair as its next growth engine
proactiveinvestors.com · Jun 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.